A Study Of The Effect Of Berberine On Glucolipid Metabolism And Cognitive Function In Schizophrene Treated By Risperidone

Objective: This study aimed at investigating the efficacy on glucolipid metabolic abnormalities and cognition in the berberine’s treatment of patients with schizophrenia.Methods: Take the method of random, double blindness and placebo control for the research. 64 objects were choosed, who meet the DSM-Ⅳ diagnostic criteria for schizophrenia. Then they were assigned to two groups with age- and gender-matched randomly: placebo control(n=33) were continued to keep the treatment of Risperidone; BBR group(n=31) who were added to berberine(300 mg, TID) without changing their previous therapy for 12 weeks. All Patients were measured on waist circumference, hip circumferenee, weight, height, then count BMI and WHR before and after the study. The Plasma levels of TG, TC, HDL-C, LDL-C, Apo-A1, Apo-B, HBAIC, Fins also be determinated, and count HOMA-IR to estimate Insulinre sistanee. PANSS was applied to assess the severity of disease, CGI, TESS was applied to evaluate the effect of the Berberine and MATRICS was applied to assess the cognitive function of patient. Repeating the same process after the treatment. Using SPSS17.0 statistical software to conduct all statistical analysis, P<0.05 was identified as statistically significance.Result: 1、Comparing with the baseline, the berberine group demonstrated significantly improvement in weight, BMI, waist and hip circumference(P<0.05),and show significantly difference in hip circumference compared with the placebo group(P<0.05),however there was no remarkable change in WHR(P>0.05). The placebo group demonstrated remarkable increasing in weight, BMI, waist hip circumference, and the hipline increased more than waistline, so the WHR somehow decreased. 2、The differences were remarkable of the decline of FPG、Fins and HOMA-IR levels after the treatment of berberine(P<0.01), and no remarkable change in Hb Alc was observed. The placebo group demonstrated significantly increasing in FPG、Hb Alc,and a trend of declining of Fins and HOMA-IR(P>0.05). 3、The differences were remarkable of the decline of TC、TG、LDL、APOB、Lp(a)(P<0.01) levels and the increase of Apo A1 after the treatment of berberine.There is a significant difference in TC、TG、LDL、APOB、HDL between the two group P<0.05), but not Lp(a). The placebo group demonstrated significantly increasing in TC、TG、LDL、APOB,and a slightly decreasing in HDL and Lp(a) with no statistic significance(P>0.05). 4、Comparing with the baseline, the berberine group demonstrated significantly improvement in the cognitive function of processing speed、the third trial of the HVLT score、the BVMT score and the 2D trial of CPT. No significantly improvement was observed on the score of WEST. 5、Subjects receiving berberine had greater improvements on CGI scores and all the item score of PANSS when compared with those receiving the placebo. The PANSS positive subscale scores have been significantly improved(P<0.05). 6、The incidence rate of weight and blood glucose increasing was much more lower than the placebo group, the other adverse reactions occurence has no statistically defference between the two groups(P>0.05).Conclusion: 1、Berberine can significantly decrease the weight, BMI, waist circumference, hip circumference of schizophrenia patients with Risperidone treatment. 2、Berberine demonstrated significantly improvement in glucolipid metabolism of schizophrenia patients with Risperidone treatment. 3、Berberine can improve the cognition function of patients with schizophrenia in processing speed and visual memory. 4、Berberine combined with Risperidone is safety when applying in clinical medication.